155 related articles for article (PubMed ID: 19467962)
1. Treatment of multiple, multiform actinic keratoses on the head with imiquimod 5% cream.
Stockfleth E; Ulrich C; Lange-Asschenfeldt B; Kremer HJ; Drecoll U; Maus J; Röwert-Huber J
Eur J Dermatol; 2009; 19(4):355-9. PubMed ID: 19467962
[TBL] [Abstract][Full Text] [Related]
2. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.
Stockfleth E; Sterry W; Carey-Yard M; Bichel J
Br J Dermatol; 2007 Dec; 157 Suppl 2():41-6. PubMed ID: 18067631
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
5. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
Peris K; Stockfleth E; Gupta G; Aractingi S; Dakovic R; Dirschka T; Alomar A
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2470-3. PubMed ID: 25351284
[TBL] [Abstract][Full Text] [Related]
7. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
Gebauer K; Shumack S; Cowen PS
Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases.
Stockfleth E; Meyer T; Benninghoff B; Christophers E
Br J Dermatol; 2001 May; 144(5):1050-3. PubMed ID: 11359396
[TBL] [Abstract][Full Text] [Related]
9. Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head.
Rivers JK; Rosoph L; Provost N; Bissonnette R
J Cutan Med Surg; 2008; 12(3):97-101. PubMed ID: 18544290
[TBL] [Abstract][Full Text] [Related]
10. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
Strohal R; Kerl H; Schuster L
J Drugs Dermatol; 2012 May; 11(5):574-8. PubMed ID: 22527424
[TBL] [Abstract][Full Text] [Related]
11. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses.
Akarsu S; Aktan S; Atahan A; Koç P; Özkan S
Clin Exp Dermatol; 2011 Jul; 36(5):479-84. PubMed ID: 21418281
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.
Ortonne JP; Gupta G; Ortonne N; Duteil L; Queille C; Mallefet P
Exp Dermatol; 2010 Jul; 19(7):641-7. PubMed ID: 20201959
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
[TBL] [Abstract][Full Text] [Related]
16. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.
Hanke CW; Swanson N; Bruce S; Berman B; Kulp J; Levy S
J Drugs Dermatol; 2011 Feb; 10(2):165-70. PubMed ID: 21283921
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.
Stockfleth E; Meyer T; Benninghoff B; Salasche S; Papadopoulos L; Ulrich C; Christophers E
Arch Dermatol; 2002 Nov; 138(11):1498-502. PubMed ID: 12437457
[TBL] [Abstract][Full Text] [Related]
18. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head.
Alomar A; Bichel J; McRae S
Br J Dermatol; 2007 Jul; 157(1):133-41. PubMed ID: 17501955
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Quist SR; Gollnick HP
Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
[TBL] [Abstract][Full Text] [Related]
20. Visualization and treatment of subclinical actinic keratoses with topical imiquimod 5% cream: an observational study.
Kopera D; Kerl H
Biomed Res Int; 2014; 2014():135916. PubMed ID: 24900953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]